A Prospective, Multicenter, Open-label, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Prophylactic VGA039 in Adolescent and Adult Patients with von Willebrand Disease (VIVID-6)

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-522056-10-01

Acronym

VGA039-CP002

Enrollment

Registered

2025-12-08

Start date

Unknown

Completion date

Unknown

Last updated

2026-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

von Willebrand Disease

Brief summary

Annualized bleeding rate (ABR)

Interventions

DRUGVGA039

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Annualized bleeding rate (ABR)	—

Countries

Austria, Germany, Ireland, Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026